Glenmark FDA Inspection - 5 observations for US Facility

Glenmark Pharmaceuticals (

) announced that the U.S. Food and Drug Administration (FDA) has completed its Good Manufacturing Practice (GMP) inspection of its Monroe, North Carolina facility from June 9–17. The agency issued a Form 483 with five observations, all described by Glenmark as procedural in nature, with no issues related to data integrity. The company has committed to addressing these observations and responding to the FDA within the stipulated timeframe. While the findings are not critical, failure to resolve them in a timely and satisfactory manner could lead to further regulatory scrutiny. If unresolved, such observations may escalate to warning letters or even consent decrees, which can severely impact a company’s manufacturing operations and export licenses. In extreme cases, the FDA may impose export bans on products manufactured at the cited facility, affecting global supply chains and revenue. Given Glenmark’s growing presence in the U.S. market and recent DCGI approval for its oncology drug BRUKINSA, maintaining compliance is crucial for sustaining its international expansion and reputation.